Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK/HIF-1 pathway inhibition in vivo.

In conclusion, the present study demonstrated that ZOL significantly increased the sensitivity of breast cancer cells to fulvestrant through inhibition of the ERK/HIF-1α pathway. PMID: 29393454 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29393454?dopt=Abstract

Source: Molecular Medicine Reports - February 4, 2018 Category: Molecular Biology Tags: Mol Med Rep Source Type: research